Can a pill stop the stomach bug? new oral norovirus vaccine put to the test
NCT ID NCT06944717
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether a new oral vaccine can safely protect against norovirus, the highly contagious virus that causes vomiting and diarrhea. Healthy adults aged 18 to 80 will receive a single dose of the vaccine, which targets two common norovirus strains. Researchers will monitor for side effects and measure the immune response in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral norovirus vaccine targeting two strains (G1.1 and G2.4)
- What this could lead to
- If successful, this could lead to a convenient oral vaccine that protects against the highly contagious norovirus stomach bug.
- What could go wrong
- This is an early phase 1 trial with only 60 participants, so safety and immune response are still unproven. The vaccine may not generate strong enough protection or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOROVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johnson County Clin Trials - JCCT
Lenexa, Kansas, 66219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.